Pulmonary autograft for aortic valve replacement in rheumatic disease: A caveat

Al‐Halees, Zohair; Kumar, Naresh; Gallo, Ricardo; Gometza, Begonia; Durán, Carlos M.G.

doi:10.1016/0003-4975(95)00317-e

Cited by 31 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is no question that there will be a small percentage of our rheumatic patients (especially among the very young) who will have recurrent rheumatic activity that will affect the autograft, just as is the case with the classic Ross procedure. 18 However, this mishap can probably be largely avoided by proper prophylaxis, and we do not believe it is a good reason to deny the benefits of the operation to the majority of our mitral patients. Whether patients with atrial fibrillation should be offered this operation remains an issue.…”

Section: Discussionmentioning

confidence: 90%

Update on the mitral pulmonary autograft

Kabbani

Sabbagh

Kudsi

et al. 2011

Asian Cardiovasc Thorac Ann

View full text Add to dashboard Cite

Between July 1997 and August 2004, 92 patients with irreparable mitral valves underwent replacement with a pulmonary autograft. This report brings the follow-up data of these patients up to date. Eighty-eight patients had a successful Ross II operation; 4 were lost to follow-up. The mean follow-up period was 94 months. Transesophageal echocardiography revealed a successful outcome in all 88 patients immediately after the operation. Operative mortality was 4.6%, and late mortality definitely related to the operation was 12.5%. At a mean follow-up of 94 months, freedom from structural valve deterioration (significant mitral stenosis and/or regurgitation) was 93.4%, freedom from reoperation was 92.0%, and freedom from all causes of death was 82.9%. Two autografts were explanted because of endocarditis. Two patients developed significant pulmonary stenosis, one of whom underwent operative repair. These data compare favorably with those of mitral valve replacement using modern bioprostheses. This procedure remains an option for the relatively young patient when life-long anticoagulation is contraindicated or impractical. It is also an option to consider in infants with complex irreparable mitral valve disease.

show abstract

Section: Discussionmentioning

confidence: 90%

Update on the mitral pulmonary autograft

Kabbani

Sabbagh

Kudsi

et al. 2011

Asian Cardiovasc Thorac Ann

View full text Add to dashboard Cite

show abstract

“…Immune‐mediated aortic valve disease 24 (systemic lupus eritematosus, ankylosing spondilytis, and Reiter syndrome) could affect the integrity of the pulmonary valve. Active rheumatic fever should be considered a relative contraindication due to its potential to affect the pulmonary valve 25 …”

Section: Methodsmentioning

confidence: 99%

The Ross Procedure

Concha

Aranda

Casares

et al. 2004

Journal of Cardiac Surgery

View full text Add to dashboard Cite

show abstract

“…AI-Halees and Carlos Duran [23] reported in 1995, their results with pulmonary autograft for aortic valve replacement in rheumatic disease. They reported their experience in 78 cases, of whom 64 patients were rheumatic.…”

Section: The Ross Proceduresmentioning

confidence: 97%

Search for the best heart valve- from replacement to repair

Satsangi

2011

Indian J Thorac Cardiovasc Surg

View full text Add to dashboard Cite

Pulmonary autograft for aortic valve replacement in rheumatic disease: A caveat

Cited by 31 publications

References 27 publications

Update on the mitral pulmonary autograft

Update on the mitral pulmonary autograft

The Ross Procedure

Search for the best heart valve- from replacement to repair

Contact Info

Product

Resources

About